The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer: a cross sectional study in France and Germany

被引:2
|
作者
Chouaid, Christos [1 ]
Giannopoulou, Andromachi [2 ]
Starry, Alexandra [3 ]
Stollenwerk, Bjoern [2 ]
Bozorgmehr, Farastuk [4 ,5 ,6 ,7 ,8 ]
机构
[1] UPEC, Serv Pneumol, CHI Creteil, Inserm U955,IMRB, Creteil, France
[2] Amgen Europe Hlth Econ & Outcomes Res, Rotkreuz, Switzerland
[3] Cytel, Berlin, Germany
[4] Heidelberg Univ Hosp, Dept Thorac Oncol, Thoraxklin, Heidelberg, Germany
[5] NCT Heidelberg, Natl Ctr Tumor Dis NCT, partnership DKFZ, Heidelberg, Germany
[6] Heidelberg Univ Hosp, Heidelberg, Germany
[7] Translat Lung Res Ctr Heidelberg TLRC H, Heidelberg, Germany
[8] German Ctr Lung Res DZL, Heidelberg, Germany
关键词
Health-related quality of life; KRAS; real-world data; non-small-cell lung cancer; patient-reported outcome; symptom burden; I00; I; I19; I1; QUALITY-OF-LIFE; SYMPTOM BURDEN; CLINICAL-TRIALS; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER; DOCETAXEL;
D O I
10.1080/13696998.2024.2437324
中图分类号
F [经济];
学科分类号
02 ;
摘要
ObjectivesHealth-related quality of life (HRQoL) studies in patients with advanced non-small-cell lung cancer (NSCLC) according to KRAS mutational status are limited. This study aimed to report real-world evidence on HRQoL outcomes based on KRAS mutational status in patients with advanced NSCLC tumors receiving second-line or later (2L+) treatment in France and Germany.MethodsIn this real-world, non-interventional, cross-sectional, multicenter, patient-reported outcome (PRO) study conducted in France (15 contributing sites) and Germany (8 contributing sites), physicians enrolled adult patients with locally advanced and unresectable or metastatic NSCLC with known KRAS mutation status (KRAS G12C, KRAS non-G12C, or KRAS wildtype [WT]), who received a 2L + treatment. Study outcomes included sociodemographic characteristics; HRQoL evaluations based on EORTC Global Health Status QoL scores (QLQ-C30) and EQ-5D-5L scores. Data were analyzed descriptively.ResultsOf 156 enrolled patients, data from 149 patients were included in the final analysis (France, n = 103; Germany, n = 46). Median (quartile [Q]1, Q3) age was 67.0 (61.0, 71.0) years; 56.4% of patients were male. In total, 38.9% (n = 58), 26.2% (n = 39), and 34.9% (n = 52) of patients had tumors with KRAS G12C mutation, KRAS non-G12C mutation and WT KRAS, respectively. Mean (+/- SD) QLQ-C30 Global Health Status QoL scores were 56.99 (20.30) for the overall population, and 56.03 (22.55), 58.97 (18.67) and 56.57 (19.05) for KRAS G12C, non-G12C, and WT subpopulations. In the overall population, moderate-to-extreme problems were reported in all EQ-5D-5L dimensions (range: overall population, 15.5%-39.6%; KRAS G12C, 15.6%-46.6%; non-G12C, 7.8%-23.1%; WT, 21.1%-44.2%).ConclusionHRQoL was broadly similar across KRAS G12C, non-G12C, and WT subpopulations.
引用
收藏
页码:13 / 24
页数:12
相关论文
共 50 条
  • [31] Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
    Peters, Solange
    Shaw, Alice T.
    Besse, Benjamin
    Felip, Enriqueta
    Solomon, Benjamin J.
    Soo, Ross A.
    Bearz, Alessandra
    Gadgeel, Shirish M.
    Lin, Chia-Chi
    Kao, Steven
    Seto, Takashi
    Masters, Elizabeth T.
    Abbattista, Antonello
    Clancy, Jill S.
    Thurm, Holger
    Reisman, Arlene
    Peltz, Gerson
    Camidge, D. Ross
    LUNG CANCER, 2020, 144 : 10 - 19
  • [32] Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
    Hui, Rina
    Ozguroglu, Mustafa
    Villegas, Augusto
    Daniel, Davey
    Vicente, David
    Murakami, Shuji
    Yokoi, Takashi
    Chiappori, Alberto
    Lee, Ki Hyeong
    de Wit, Maike
    Cho, Byoung Chul
    Gray, Jhanelle E.
    Ryden, Anna
    Viviers, Louis
    Poole, Lynne
    Zhang, Yiduo
    Dennis, Phillip A.
    Antonia, Scott J.
    LANCET ONCOLOGY, 2019, 20 (12): : 1670 - 1680
  • [33] Limited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer
    Li, Hong-Shuai
    Liu, Cheng-Ming
    Wang, Yan
    FUTURE ONCOLOGY, 2022, 18 (19) : 2433 - 2443
  • [34] Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer
    Reck, Martin
    Wehler, Thomas
    Orlandi, Francisco
    Nogami, Naoyuki
    Barone, Carlo
    Moro-Sibilot, Denis
    Shtivelband, Mikhail
    Gonzalez Larriba, Jose Luis
    Rothenstein, Jeffrey
    Fruh, Martin
    Yu, Wei
    Deng, Yu
    Coleman, Shelley
    Shankar, Geetha
    Patel, Hina
    Kelsch, Claudia
    Lee, Anthony
    Piault, Elisabeth
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (22) : 2530 - +
  • [35] Outcomes of chemoradiation for patients with locally advanced non-small-cell lung cancer
    Spina, R.
    Chu, S. Y. Y.
    Chatfield, M.
    Chen, J.
    Tin, M. M.
    Boyer, M.
    INTERNAL MEDICINE JOURNAL, 2013, 43 (07) : 790 - 797
  • [36] Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient
    Fu, Yang
    Zheng, Yue
    Wang, Pei-Pei
    Chen, Yue-Yun
    Ding, Zhen-Yu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [37] Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy
    Wang, Xin Shelley
    Shi, Qiuling
    Williams, Loretta A.
    Komaki, Ritsuko
    Gomez, Daniel R.
    Lin, Steven H.
    Chang, Joe Y.
    O'Reilly, Michael S.
    Bokhari, Raza H.
    Cox, James D.
    Mohan, Radhe
    Cleeland, Charles S.
    Liao, Zhongxing
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2016, 51 (05) : 832 - 838
  • [38] Long-term patient-reported outcomes after non-small cell lung cancer resection
    Heiden, Brendan T.
    Subramanian, Melanie P.
    Liu, Jingxia
    Keith, Angela
    Engelhardt, Kathryn E.
    Meyers, Bryan F.
    Puri, Varun
    Kozower, Benjamin D.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2022, 164 (03): : 615 - +
  • [39] Comparison of early patient-reported outcomes between uniportal thoracoscopic segmentectomy and wedge resection for peripheral small-sized non-small-cell lung cancer
    Zhao, Yingzhi
    Liu, Wenwu
    Gao, Xin
    Zhang, Kaixin
    Dai, Wei
    Wei, Xing
    Zheng, Haoqian
    Lei, Cheng
    Yu, Hongfan
    Shi, Qiuling
    Li, Qiang
    Xie, Tianpeng
    JOURNAL OF CARDIOTHORACIC SURGERY, 2024, 19 (01)
  • [40] Impact of KRAS mutation on non-small cell lung cancer survival outcomes
    Thomas, Q.
    Lemercier, P.
    Justeau, G.
    Schneider, S.
    Filleron, T.
    Masip, J. Remon
    Perol, M.
    Girard, N.
    Debieuvre, D.
    Valette, C. Audigier
    Chouaid, C.
    Loeb, A.
    Hiret, S.
    Clement-Duchene, C.
    Dansin, E.
    Stancu, A. T.
    Dubray-Longeras, P.
    Pichon, E.
    Bosquet, L.
    Quantin, X.
    ANNALS OF ONCOLOGY, 2023, 34